How We Can Bring Gene Therapies To Bear On Diseases Of Aging

By Chris Learn, Ph.D., P.M.P., Senior Vice President, Head of the Cell and Gene Center of Excellence

This article explores the evolving landscape of clinical trials focused on Alzheimer’s and Dementia, underscoring persistent challenges and emerging opportunities in developing precise treatments for diseases associated with aging. It highlights the urgent necessity of including older adults in clinical research, pointing out their historical underrepresentation due to implicit age biases and strict eligibility criteria.

Additionally, the article examines advancements in gene editing technologies, which hold promise for addressing unmet medical needs in central nervous system (CNS) disorders like Alzheimer’s. Despite current obstacles in trial design and recruitment of suitable participants, the discussion emphasizes the potential of these technologies.

The article concludes with a call to action, advocating for more inclusive trial practices, the use of advanced analytics, and the adoption of innovative stratification methods. These approaches are crucial for accelerating the development of therapies specifically tailored to older patient populations.

For a deeper exploration, please refer to the full article below.